The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.
E. Lou
No relevant relationships to disclose
D. A. Reardon
Consultant or Advisory Role - Roche/Genentech; Schering-Plough
Honoraria - Roche/Genentech; Schering-Plough
K. Peters
No relevant relationships to disclose
A. Desjardins
No relevant relationships to disclose
J. E. Herndon
No relevant relationships to disclose
A. D. Coan
No relevant relationships to disclose
S. G. Turner
No relevant relationships to disclose
A. L. Sumrall
No relevant relationships to disclose
L. Bailey
No relevant relationships to disclose
H. S. Friedman
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
J. J. Vredenburgh
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech